The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Molteni, Monica ^a   Gemma, Sabrina ^a   Rossetti, Carlo ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR 4; PATTERN RECOGNITION RECEPTOR;

ACUTE HEART INFARCTION; CARDIAC MUSCLE CELL; CELL SURFACE; CONFORMATIONAL TRANSITION; CYANOBACTERIUM; DEGENERATIVE DISEASE; ENDOTHELIUM CELL; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; INFECTION; INFLAMMATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; PHYSIOLOGY;

ANIMALS; HUMANS; INFLAMMATION; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84973330893     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/6978936     Document Type: Review

References (102)

1. S. Akira and K. Takeda, "Toll-like receptor signaling," Nature Reviews Immunology, vol. 4, no. 7, pp. 1-16, 2004.
2. L. Yu, L. Wang, and S. Chen, "Endogenous toll-like receptor ligands and their biological significance," Journal of Cellular and Molecular Medicine, vol. 14, no. 11, pp. 2592-2603, 2010.
3. K. R. Taylor, J.M. Trowbridge, J. A. Rudisill, C. C. Termeer, J. C. Simon, and R. L. Gallo, "Hyaluronan fragments stimulate endothelial recognition of injury through TLR4," The Journal of Biological Chemistry, vol. 279, no. 17, pp. 17079-17084, 2004.
4. S. Frantz, L. Kobzik, Y.-D. Kim et al., "Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium," The Journal of Clinical Investigation, vol. 104, no. 3,pp. 271-280, 1999.
5. T. Kielian, "Toll-like receptors in CNS glial inflammation and homeostasis," Journal of Neuroscience Research, vol. 83, no. 5, pp. 711-730, 2006.
6. R. Medzhitov, P. Preston-Hurlburt, and C. A. Janeway Jr., "A human homologue of the Drosophila toll protein signals activation of adaptive immunity," Nature, vol. 388, no. 6640, pp. 394-397, 1997.
7. Y. Nagai, S. Akashi, M. Nagafuku et al., "Essential role of MD-2 in LPS responsiveness and TLR4 distribution," Nature Immunology, vol. 3, no. 7, pp. 667-672, 2002.
8. A. B. Schromm, E. Lien, P. Henneke et al., "Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxininduced signaling," The Journal of Experimental Medicine, vol. 194, no. 1, pp. 79-88, 2001.
9. R. Shimazu, S. Akashi, H. Ogata et al., "MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4," Journal of Experimental Medicine, vol. 189, no. 11, pp. 1777-1782, 1999.
10. S. Viriyakosol, P. S. Tobias, R. L. Kitchens, and T. N. Kirkland, "MD-2 binds to bacterial lipopolysaccharide," The Journal of Biological Chemistry, vol. 276, no. 41, pp. 38044-38051, 2001.
11. H. M. Kim, B. S. Park, J.-I. Kim et al., "Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran," Cell, vol. 130, no. 5, pp. 906-917, 2007.
12. B. S. Park, D. H. Song, H. M. Kim, B.-S. Choi, H. Lee, and J.-O. Lee, "The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex," Nature, vol. 458, no. 7242, pp. 1191-1195, 2009.
13. U. Ohto, K. Fukase, K. Miyake, and T. Shimizu, "Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 19, pp. 7421-7426, 2012.
14. I.Zanoni, R. Ostuni, L. R. Marek et al., "CD14 controls the LPSinduced endocytosis of toll-like receptor 4," Cell, vol. 147, no. 4, pp. 868-880, 2011.
15. G. M. Barton and R. Medzhitov, "Toll-like receptor signaling pathways," Science, vol. 300, no. 5625, pp. 1524-1525, 2003.
16. R. Rajaiah, D. J. Perkins, D. D. C. Ireland, and S.N. Vogel, "CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance," Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 27, pp. 8391-8396, 2015.
17. M. A. Nahid, K. M. Pauley, M. Satoh, and E. K. L. Chan, "miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity," The Journal of Biological Chemistry, vol. 284, no. 50, pp. 34590-34599, 2009.
18. L. A. O'Neill, F. J. Sheedy, and C. E. McCoy, "MicroRNAs: the fine-tuners of Toll-like receptor signalling," Nature Reviews Immunology, vol. 11, no. 3, pp. 163-175, 2011.
19. A. Poltorak, X. He, I. Smirnova et al., "Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene," Science, vol. 282, no. 5396, pp. 2085-2088, 1998.
20. S. T. Qureshi, L. Larivière, G. Leveque et al., "Endotoxintolerant mice have mutations in toll-like receptor 4 (Tlr4)," Journal of Experimental Medicine, vol. 189, no. 4, pp. 615-625, 1999.
21. E. A.Kurt-Jones, L. Popova, L.Kwinn et al., "Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus," Nature Immunology, vol. 1, no. 5, pp. 398-401, 2000.
22. T. H. Flo, L. Ryan, E. Latz et al., "Involvement of Toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers,"The Journal of Biological Chemistry, vol. 277, no. 38, pp. 35489-35495, 2002.
23. S. Yang, S. Sugawara, T. Monodane et al., "Micrococcus luteus teichuronic acids activate human andmurinemonocytic cells in a CD14-and toll-like receptor 4-dependent manner," Infection and Immunity, vol. 69, no. 4, pp. 2025-2030, 2001.
24. P. Rallabhandi, J. Bell, M. S. Boukhvalova et al., "Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling," The Journal of Immunology, vol. 177, no. 1, pp. 322-332, 2006.
25. K. Gomi, K. Kawasaki, Y. Kawai, M. Shiozaki, and M. Nishijima, "Toll-like receptor 4-MD-2 complex mediates the signal transduction induced by flavolipin, an amino acid-containing lipid unique to Flavobacterium meningosepticum," The Journal of Immunology, vol. 168, no. 6, pp. 2939-2943, 2002.
26. L. Romani, "Immunity to fungal infections," Nature Reviews Immunology, vol. 11, no. 4, pp. 275-288, 2011.
27. N. Modhiran, D. Watterson, D. A. Muller et al., "Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cellmonolayer integrity," Science Translational Medicine, vol. 7, no. 304,Article ID 304ra142, 2015.
28. K. Kawasaki, S. Akashi, R. Shimazu, T. Yoshida, K. Miyake, and M. Nishijima, "Mouse toll-like receptor 4·MD-2 complex mediates lipopolysaccharide - mimetic signal transduction by Taxol," The Journal of Biological Chemistry, vol. 275, no. 4, pp. 2251-2254, 2000.
29. G.D.Kutuzova, R.M. Albrecht,C.M.Erickson, andN.Qureshi, "Diphosphoryl lipid A fromRhodobacter sphaeroides blocks the binding and internalization of lipopolysaccharide inRAW264.7 cells," The Journal of Immunology, vol. 167, no. 1, pp. 482-489, 2001.
30. A. Macagno, M. Molteni, A. Rinaldi et al., "A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression," Journal of Experimental Medicine, vol. 203, no. 6, pp. 1481-1492, 2006.
31. C. Termeer, F. Benedix, J. Sleeman et al., "Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4," The Journal of Experimental Medicine, vol. 195, no. 1, pp. 99-111, 2002.
32. L. Schaefer, A. Babelova, E. Kiss et al., "The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages," The Journal of Clinical Investigation, vol. 115, no. 8, pp. 2223-2233, 2005.
33. S. P. Gondokaryono, H. Ushio, F. Niyonsaba et al., "The extra domain A of fibronectin stimulates murine mast cells via tolllike receptor 4," Journal of Leukocyte Biology, vol. 82, no. 3, pp. 657-665, 2007.
34. G. B. Johnson, G. J. Brunn, Y. Kodaira, and J. L. Platt, "Receptormediated monitoring of tissue well-being via detection of soluble heparan sulfate by toll-like receptor 4," Journal of Immunology, vol. 168, no. 10, pp. 5233-5239, 2002.
35. K. Midwood, S. Sacre, A. M. Piccinini et al., "Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease," Nature Medicine, vol. 15, no. 7, pp. 774-780, 2009.
36. M. T. Lotze and K. J. Tracey, "High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal," Nature Reviews Immunology, vol. 5, no. 4, pp. 331-342, 2005.
37. M. F. Roelofs, W. C. Boelens, L. A. B. Joosten et al., "Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis," Journal of Immunology, vol. 176, no. 11,pp. 7021-7027, 2006.
38. K. Ohashi, V. Burkart, S. Flohé, andH. Kolb, "Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex," The Journal of Immunology, vol. 164, no. 2, pp. 558-561, 2000.
39. A.Asea, M. Rehli, E. Kabingu et al., "Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4," Journal of Biological Chemistry, vol. 277, no. 17, pp. 15028-15034, 2002.
40. M. A. Chase, D. S. Wheeler, K. M. Lierl, V. S. Hughes, H. R. Wong, and K. Page, "Hsp72 induces inflammation and regulates cytokine production in airway epithelium through a TLR4-and NF-κB-dependentmechanism,"TheJournal of Immunology, vol. 179, no. 9, pp. 6318-6324, 2007.
41. H. Fang, Y. Wu, X. Huang et al., "Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response," The Journal of Biological Chemistry, vol. 286, no. 35, pp. 30393-30400, 2011.
42. R. M. Vabulas, S. Braedel, N. Hilf et al., "The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the toll-like receptor 2/4 pathway," Journal of Biological Chemistry, vol. 277, no. 23, pp. 20847-20853, 2002.
43. W. Wu, Q. Chen, F. Geng et al., "Calcineurin B stimulates cytokine production through a CD14-independent Toll-like receptor 4 pathway," Immunology and Cell Biology, vol. 94, no. 3, pp. 285-292, 2015.
44. A. Biragyn, P. A. Ruffini, C. A. Leifer et al., "Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2," Science, vol. 298, no. 5595, pp. 1025-1029, 2002.
45. T. Vogl, K. Tenbrock, S. Ludwig et al., "Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock," Nature Medicine, vol. 13, no. 9, pp. 1042-1049, 2007.
46. L. Guillot, V. Balloy, F. X. McCormack, D. T. Golenbock, M. Chignard, and M. Si-Tahar, "Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Tolllike receptor 4,"The Journal of Immunology, vol. 168, no. 12, pp. 5989-5992, 2002.
47. A. Tarkowski, J. Bjersing, A. Shestakov, and M. I. Bokarewa, "Resistin competes with lipopolysaccharide for binding to tolllike receptor 4," Journal of Cellular andMolecularMedicine, vol. 14, no. 6, pp. 1419-1431, 2010.
48. S. T. Smiley, J. A. King, and W. W. Hancock, "Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4," Journal of Immunology, vol. 167, no. 5, pp. 2887-2894, 2001.
49. C. R. Stewart, L. M. Stuart, K. Wilkinson et al., "CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer," Nature Immunology, vol. 11, no. 2, pp. 155-161, 2010.
50. C. Erridge, "Endogenous ligands of TLR2 and TLR4: agonists or assistants?" Journal of Leukocyte Biology, vol. 87, no. 6, pp. 989-999, 2010.
51. D. Jiang, J. Liang, J. Fan et al., "Regulation of lung injury and repair by Toll-like receptors and hyaluronan," Nature Medicine, vol. 11, no. 11, pp. 1173-1179, 2005.
52. S. Lehnardt, E. Schott, T. Trimbuch et al., "A vicious cycle involving release of heat shock protein 60 frominjured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS," The Journal of Neuroscience, vol. 28, no. 10, pp. 2320-2331, 2008.
53. H. Yang, H. S. Hreggvidsdottir, K. Palmblad et al., "A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 26, pp. 11942-11947, 2010.
54. K. Hoshino, O. Takeuchi, T. Kawai et al., "Cutting edge: tolllike receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product," The Journal of Immunology, vol. 162, no. 7, pp. 3749-3752, 1999.
55. A. D. O'Brien, D. L. Rosenstreich, I. Scher, G. H. Campbell, R. P. MacDermott, and S. B. Formal, "Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene," The Journal of Immunology, vol. 124, no. 1, pp. 20-24, 1980.
56. J. P. Woods, J. A. Frelinger, G. Warrack, and J. G. Cannon, "Mouse genetic locus Lps influences susceptibility to Neisseria meningitidis infection," Infection and Immunity, vol. 56, no. 8, pp. 1950-1955, 1988.
57. T. Roger, C. Froidevaux,D. Le Roy et al., "Protection fromlethal gram-negative bacterial sepsis by targeting Toll-like receptor 4," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 7, pp. 2348-2352, 2009.
58. M. G. Netea, C. Wijmenga, and L. A. J. O'Neill, "Genetic variation in Toll-like receptors and disease susceptibility," Nature Immunology, vol. 13, no. 6, pp. 535-542, 2012.
59. B. Ferwerda, M. B. B. McCall, K. Verheijen et al., "Functional consequences of toll-like receptor 4 polymorphisms,"Molecular Medicine, vol. 14, no. 5-6, pp. 346-352, 2008.
60. T. Fukusaki, N. Ohara, Y. Hara,A. Yoshimura, and K. Yoshiura, "Evidence for association between a Toll-like receptor 4 gene polymorphism and moderate/severe periodontitis in the Japanese population," Journal of Periodontal Research, vol. 42, no. 6, pp. 541-545, 2007.
61. A. Mansur, L. von Gruben, A. F. Popov et al., "The regulatory toll-like receptor 4 genetic polymorphism rs11536889 is associated with renal, coagulation and hepatic organ failure in sepsis patients," Journal of Translational Medicine, vol. 12, no. 1, pp. 177-185, 2014.
62. K. Sato, A. Yoshimura, T. Kaneko et al., "A single nucleotide polymorphism in 3'-untranslated region contributes to the regulation of toll-like receptor 4 translation," Journal of Biological Chemistry, vol. 287, no. 30, pp. 25163-25172, 2012.
63. S.M.Opal, P. F. Laterre, B. Francois et al., "Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial," Journal of the American Medical Association, vol. 309, no. 11, pp. 1154-1162, 2013.
64. N. A. Hutchins, J. Unsinger, R. S. Hotchkiss, and A. Ayala, "The newnormal: immunomodulatory agents against sepsis immune suppression," Trends in Molecular Medicine, vol. 20, no. 4, pp. 224-233, 2014.
65. M. Andrassy, H. C. Volz, J. C. Igwe et al., "High-mobility group box-1 in ischemia-reperfusion injury of the heart," Circulation, vol. 117, no. 25, pp. 3216-3226, 2008.
66. R. F. van Golen, T. M. van Gulik, and M. Heger, "The sterile immune response during hepatic ischemia/reperfusion," Cytokine and Growth Factor Reviews, vol. 23, no. 3, pp. 69-84, 2012.
67. D. M. Yellon and D. J. Hausenloy, "Myocardial reperfusion injury," The New England Journal of Medicine, vol. 357, no. 11, pp. 1074-1135, 2007.
68. J. Howell, P. Gow, P. Angus, and K. Visvanathan, "Role of tolllike receptors in liver transplantation," Liver Transplantation, vol. 20, no. 3, pp. 270-280, 2014.
69. J.-I. Oyama, C. Blais Jr., X. Liu et al., "Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice," Circulation, vol. 109, no. 6, pp. 784-789, 2004.
70. D. J. Kaczorowski, A. Nakao, R. Vallabhaneni et al., "Mechanisms of Toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart," Transplantation, vol. 87, no. 10, pp. 1455-1463, 2009.
71. A. Tsung, R. Sahai, H. Tanaka et al., "The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemiareperfusion," Journal of Experimental Medicine, vol. 201, no. 7, pp. 1135-1143, 2005.
72. J. R. Caso, J. M. Pradillo, O. Hurtado, P. Lorenzo, M. A. Moro, and I. Lizasoain, "Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke," Circulation, vol. 115, no. 12, pp. 1599-1608, 2007.
73. H.Wu,G. Chen, K. R.Wyburn et al., "TLR4 activationmediates kidney ischemia/reperfusion injury," Journal of Clinical Investigation, vol. 117, no. 10, pp. 2847-2859, 2007.
74. F. Hua, J. Ma, T. Ha et al., "Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion," Journal of Neuroimmunology, vol. 190, no. 1-2, pp. 101-111, 2007.
75. A. J. Chong, A. Shimamoto, C. R. Hampton et al., "Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart," The Journal ofThoracic and Cardiovascular Surgery, vol. 128, no. 2, pp. 170-179, 2004.
76. D. J. Kaczorowski, A. Nakao, K. P. Mollen et al., "Toll-like receptor 4 mediates the early inflammatory response after cold ischemia/reperfusion," Transplantation, vol. 84,no. 10,pp. 1279-1287, 2007.
77. A. Shimamoto, A. J. Chong, M. Yada et al., "Inhibition of tolllike receptor 4 with eritoran attenuates myocardial ischemiareperfusion injury," Circulation, vol. 114, no. 1, pp. I270-I274, 2006.
78. A. Soldo, M.Molteni, C. Rossetti et al., "CyP, a toll-like receptor 4 antagonist, protects the heart from ischemia/reperfusion injury," European Heart Journal, vol. 32, supplement 1, p. 690, 2011.
79. K. A. Mcdonald, H. Huang, S. Tohme et al., "Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of highmobility group box protein B1 (HMGB1) signaling," Molecular Medicine, vol. 20, pp. 639-648, 2015.
80. M. T. Heneka, M. J. Carson, J. El. Khoury et al., "Neuroinflammation in Alzheimer's disease," The Lancet Neurology, vol. 14, no. 4, pp. 388-405, 2015.
81. A. Vezzani, "Epilepsy and inflammation in the brain: overview and pathophysiology," Epilepsy Currents, vol. 14, no. 1, pp. 3-7, 2014.
82. T. C. Frank-Cannon, L. T. Alto, F. E. McAlpine, and M. G. Tansey, "Does neuroinflammation fan the flame in neurodegenerative diseases?"Molecular Neurodegeneration, vol. 4, no. 1, pp. 47-60, 2009.
83. J. K. Olson and S. D. Miller, "Microglia initiate central nervous systeminnate and adaptiveimmune responses throughmultiple TLRs,"TheJournal of Immunology, vol. 173, no. 6,pp. 3916-3924, 2004.
84. A. J. Tarr, K. A. McLinden, D. Kranjac, R. A. Kohman, W. Amaral, and G. W. Boehm, "The effects of age on lipopolysaccharide-induced cognitive deficits and interleukin-1β expression," Behavioural Brain Research, vol. 217, no. 2, pp. 481-485, 2011.
85. N. Terrando, A. R. Fidalgo, M. Vizcaychipi et al., "The impact of IL-1 modulation on the development of lipopolysaccharideinduced cognitive dysfunction," Critical Care, vol. 14, article R88, 2010.
86. A. Mazarati, M. Maroso, V. Iori, A. Vezzani, and M. Carli, "High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and receptor for advanced glycation end products," Experimental Neurology, vol. 232, no. 2, pp. 143-148, 2011.
87. S.-C. Tang, J. D. Lathia, P. K. Selvaraj et al., "Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid β-peptide and the membrane lipid peroxidation product 4-hydroxynonenal," Experimental Neurology, vol. 213, no. 1, pp. 114-121, 2008.
88. S. Walter, M. Letiembre, Y. Liu et al., "Role of the tolllike receptor 4 in neuroinflammation in Alzheimer's disease," Cellular Physiology and Biochemistry, vol. 20,no. 6, pp. 247-256, 2007.
89. S. Frank, E. Copanaki, G. J. Burbach,U. C.Müller, and T.Deller, "Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice," Neuroscience Letters, vol. 453, no. 1, pp. 41-44, 2009.
90. M. A. Panaro,D.D. Lofrumento, C. Saponaro et al., "Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease," Immunopharmacology and Immunotoxicology, vol. 30, no. 4, pp. 729-740, 2008.
91. M. Casula, A. M. Iyer,W. G. M. Spliet et al., "Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue," Neuroscience, vol. 179, pp. 233-243, 2011.
92. M.De Paola, A.Mariani, P. Bigini et al., "Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration," Molecular Medicine, vol. 18, no. 6, pp. 971-981, 2012.
93. M. R.Minter, J. M. Taylor, and P. J. Crack, "The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease," Journal of Neurochemistry, vol. 136, no. 3, pp. 457-474, 2016.
94. M. Song, J. Jin, J.-E. Lim et al., "TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease," Journal of Neuroinflammation, vol. 8, pp. 92-106, 2011.
95. K. G. Mawuenyega, W. Sigurdson, V. Ovod et al., "Decreased clearance of CNS β-amyloid in Alzheimer's disease," Science, vol. 330, no. 6012, pp. 1774-1776, 2010.
96. S. E. Hickman, E. K. Allison, and J. El Khoury, "Microglial dysfunction and defective β-amyloid clearance pathways in aging alzheimer's disease mice," Journal of Neuroscience, vol. 28, no. 33, pp. 8354-8360, 2008.
97. J.-P.Michaud,M. Hallé, A. Lampron et al., "Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 5, pp. 1941-1946, 2013.
98. C. Noelker, L. Morel, T. Lescot et al., "Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease," Scientific Reports, vol. 3, article 1393, 2013.
99. N. Stefanova,L.Fellner,M.Reindl, E.Masliah,W. Poewe, andG. K. Wenning, "Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons," American Journal of Pathology, vol. 179, no. 2, pp. 954-963, 2011.
100. L. Fellner, R. Irschick, K. Schanda et al., "Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia," Glia, vol. 61, no. 3, pp. 349-360, 2013.
101. M. D. Nguyen, T.D'Aigle,G.Gowing, J.-P. Julien, and S. Rivest, "Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis," The Journal of Neuroscience, vol. 24, no. 6, pp. 1340-1349, 2004.
102. M.Maroso, S. Balosso, T. Ravizza et al., "Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures," Nature Medicine, vol. 16, no. 4, pp. 413-419, 2010.